Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.

Publication Type:

Journal Article

Source:

The Lancet infectious diseases, Volume 11, Issue 7, p.507-15 (2011)

Keywords:

2011, Center-Authored Paper, September 2011, Vaccine and Infectious Disease Division

Abstract:

The MRKAd5 HIV-1 gag/pol/nef subtype B vaccine was designed to elicit T-cell-mediated immune responses capable of providing complete or partial protection from HIV-1 infection or a decrease in viral load after acquisition. We aim to assess the safety and efficacy of the vaccine in South Africa, where the major circulating clade is subtype C.